0
0
In a recent report, the Central Drugs Standard Control Organization (CDSCO) revealed that 41 drug samples were found to be of substandard quality (NSQ) in November. The testing was conducted at central drug laboratories, where these samples failed to meet the required quality standards.
In addition to the 41 NSQ samples, state laboratories flagged another 70 drug samples that also did not meet the specified quality parameters. The identification of substandard drugs typically indicates that the samples in question do not meet the expected specifications, potentially posing risks to patient health.
CDSCO officials clarified that these concerns are limited to the specific batches tested and do not imply issues with other products available on the market. The agency also highlighted the detection of two spurious drug samples, which were being produced by unauthorized manufacturers using the brand names of established companies. One of these spurious samples was identified by the Bihar Drugs Control Authority, while the other was flagged by CDSCO, Ghaziabad.
Such findings underscore the ongoing efforts of regulatory bodies to ensure the safety and efficacy of pharmaceuticals available to consumers. However, CDSCO officials reassured the public that these actions were part of routine checks and that there was no widespread threat from other products currently in circulation.
These reports are part of the government’s continued vigilance to ensure that drugs manufactured and sold in India meet the highest standards of quality, safety, and efficacy.
(Source: Business Standard)
